### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

## **SCHEDULE 13D**

# UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)\*

### **Auris Medical Holding AG**

(Name of Issuer)
Ordinary Shares
(Title of Class of Securities)
H0381L104
(CUSIP Number)
Ha-Jin Shin Sofinnova Partners
Immeuble le Centorial
16-18 rue du Quatre-Septembre 75002 Paris
France
+33 1 53 05 41 04
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February 28, 2018
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of $\S$ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. $\square$
<b>Note:</b> Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. H0381L104 Page 2 of 10

1.	Name of F	eporting Persons		
	Sofinnova EIN: 98-1	Capital VII FCPR ("SC VII") 28040		
2.	Check the	Appropriate Box if a Member of a Group (see instructions)		
			(a) (b)	
3.	SEC USE	ONLY		
4.	Source of	Funds (see instructions)		
	WC			
5.	Check if I	isclosure of Legal Proceedings Is Required Pursuant to Items	2(d) or 2(e)	
6.	Citizenshi	or Place of Organization		
	France			
	France	7. Sole Voting Power		
Sh Benei Own Ea Repo	ber of ares ficially aed by ach orting on With	company of SC VII, may be deemed to have so Antoine Papiernik ("Papiernik"), Monique Sau Richter ("Richter"), the managing partners of Sahares.  8. Shared Voting Power  See row 7.  9. Sole Dispositive Power  331,147 shares, except that SP SAS, a French of	SAS ("SP SAS"), a French corporation and the management ole power to dispose of these shares, and Denis Lucquin ("Lucquin Inier ("Saulnier"), Graziano Seghezzi ("Seghezzi") and Henrijette SP SAS, may be deemed to have shared power to dispose of such corporation and the management company of SC VII, may be deemed Lucquin, Papiernik, Saulnier, Seghezzi and Richter, the management power to dispose of such shares.	ned
		See row 9.		
11.	Aggregate	Amount Beneficially Owned by Each Reporting Person		
	331,147 sl			
12.		e Aggregate Amount in Row (11) Excludes Certain Shares (s	ee instructions) 🗆	
13.	Dercent of	Class Represented by Amount in Row 11		
13.		Glass Represented by Amount in Row 11		
14.	5.4% (1)	porting Person (see instructions)		
14.		porting reason (see instructions)		
(1) Daged	00 on 6 117 300	shares of Assis Medical Helding AC common stock issued	and outstanding which is the number of shows of common stock	
	g as of Marc		and outstanding, which is the number of shares of common stock Form F-1 filed with the Securities and Exchange Commission ("SE	EC")

CUSIP No. H0381L104 Page 3 of 10

1.	. Name of Reporting Persons			
	Sofinnova Partners SAS, a French corporation ("SP SAS")			
2.				
		(a)		
	CEC LICE	(b)	$\boxtimes$	
3.	SEC USE	E OINLY		
4.	Source of	f Funds (see instructions)		
	00			
5.	Check if l	Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizensh	nip or Place of Organization		
	Evança			
	France	7. Sole Voting Power		
		7. Sole voting rower		
		331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may	y be	
		deemed to have sole voting power, and Lucquin, Papiernik, Saulnier, Seghezzi and Richter, the managing partner	rs of	
	Number of	SP SAS, may be deemed to have shared power to vote these shares.		
	Shares	8. Shared Voting Power		
	Beneficially			
	Owned by Each	See row 7.		
	Reporting	9. Sole Dispositive Power		
	Person With	331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII, may	v bo	
		deemed to have sole voting power, and Lucquin, Papiernik, Saulnier, Seghezzi and Richter, the managing partner		
		SP SAS, may be deemed to have shared power to vote these shares.	3 01	
		10. Shared Dispositive Power		
		See row 9.		
11.	Aggregate	te Amount Beneficially Owned by Each Reporting Person		
	331,147 s	shares		
12.	Check if t	the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) $\square$		
13.	Percent of	of Class Represented by Amount in Row 11		
	5.4% (1)			
14.		Reporting Person (see instructions)		
	00			
		88 shares of Auris Medical Holding AG common stock issued and outstanding, which is the number of shares of common stock och 26, 2018, as disclosed by Auris Medical Holding AG in its Form F-1 filed with the SEC on March 28, 2018.		
-				

CUSIP No. H0381L104 Page 4 of 10

1.	Name o	f Reportir	ng Persons		
	Denis L	Lucquin ("	Lucquin")		
2.	Check t	he Appro	priate Box if a Member of a Group (see instructions)		
				(a) (b)	
3.	SEC US	SE ONLY		( )	
4.	Source	of Funds (	(see instructions)		
	00				
5.	Check i	f Disclosu	ure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizens	ship or Pla	ace of Organization		
	French	Citizen			
		7.	Sole Voting Power		
			0		
	NT 1 C	8.	Shared Voting Power		
	Number of Shares Beneficially Owned by		331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC VI deemed to have sole voting power, and Lucquin, a managing partner of SP SAS, may be deemed to have sh to vote these shares.		
	Each Reporting	9.	Sole Dispositive Power		
	Person With		0		
		10.	Shared Dispositive Power		
			331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC VI deemed to have sole voting power, and Lucquin, a managing partner of SP SAS, may be deemed to have sh to vote these shares.		
11.	Aggreg	ate Amou	nt Beneficially Owned by Each Reporting Person		
	331,147	7 shares			
12.	Check i	f the Agg	regate Amount in Row (11) Excludes Certain Shares (see instructions)		
13.	Percent	of Class I	Represented by Amount in Row 11		
	5.4% (1	.)			
14.			g Person (see instructions)		
	IN				
			s of Auris Medical Holding AG common stock issued and outstanding, which is the number of shares of commo 018, as disclosed by Auris Medical Holding AG in its Form F-1 filed with the SEC on March 28, 2018.	n stock	

CUSIP No. H0381L104 Page 5 of 10

1.	. Name of Reporting Persons				
	Antoine Papiernik ("Papiernik")				
2.			priate Box if a Member of a Group (see instructions)		
			• • • • • • • • • • • • • • • • • • • •	(a)	
				(b)	$\boxtimes$
3.	SEC US	E ONLY			
4.	4. Source of Funds (see instructions)				
	00				
5.	Check if	Disclosu	re of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizens	hin or Pla	ace of Organization		
٠.	Grazens	p 01 1 10	ace of Organization		
	French (				
		7.	Sole Voting Power		
			0		
		8.	Shared Voting Power		
	Number of				
	Shares		331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII		
	Beneficially		deemed to have sole voting power, and Papiernik, a managing partner of SP SAS, may be deemed to have sh	ared po	wer
	Owned by Each		to vote these shares.		
	Reporting	9.	Sole Dispositive Power		
	Person With		0		
		10.	Shared Dispositive Power		
			331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII		
			deemed to have sole voting power, and Papiernik, a managing partner of SP SAS, may be deemed to have sh to vote these shares.	iared po	wer
11.	. Aggrega	te Amoui	nt Beneficially Owned by Each Reporting Person		
12	331,147		regate Amount in Row (11) Excludes Certain Shares (see instructions) □		
12	. Check ii	uie Aggi	regate Amount in Now (11) Excludes Certain Shares (see instructions)		
13	. Percent	of Class I	Represented by Amount in Row 11		
	5.4% (1)	1			
14			g Person (see instructions)		
	IN				
(1)		88 shares	s of Auris Medical Holding AG common stock issued and outstanding, which is the number of shares of common	stock	
			018, as disclosed by Auris Medical Holding AG in its Form F-1 filed with the SEC on March 28, 2018.	JUCK	

CUSIP No. H0381L104 Page 6 of 10

1.	1. Name of Reporting Persons				
	Henrijette Richter ("Richter")				
2.			priate Box if a Member of a Group (see instructions)		
				(a) (b)	
3.	SEC US	E ONLY		(-)	
4.	Source o	of Funds (	(see instructions)		
		)			
5.	00 Check it	f Disclosu	are of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
5.	Circck in	Disclose	ine of Eegal Proceedings is required 1 distant to helis 2(d) of 2(e)		
6.	Citizens	hip or Pla	ace of Organization		
	French (	Citizen			
		7.	Sole Voting Power		
			0		
		8.	Shared Voting Power		
	Number of	0.	Shared Tolking 1 over		
	Shares		331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII,	may be	e
]	Beneficially		deemed to have sole voting power, and Richter, a managing partner of SP SAS, may be deemed to have share	ed powe	er to
	Owned by		vote these shares.		
	Each Reporting	9.	Sole Dispositive Power		
	Person With		0		
		10.	Shared Dispositive Power		
		10.	Shared Dispositive Fower		
			331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC VII,	may be	е
			deemed to have sole voting power, and Richter, a managing partner of SP SAS, may be deemed to have share	ed powe	er to
			vote these shares.		
11.	Aggrega	ate Amou	nt Beneficially Owned by Each Reporting Person		
	331,147	shares			
12.	Check is	f the Aggı	regate Amount in Row (11) Excludes Certain Shares (see instructions) $\square$		
13.	Percent	of Class I	Represented by Amount in Row 11		
	E 40/ (1)	`			
14.	5.4% (1)		g Person (see instructions)		
14,		vehornii	g i cison (see manachons)		
(4)	IN				
			s of Auris Medical Holding AG common stock issued and outstanding, which is the number of shares of common 018, as disclosed by Auris Medical Holding AG in its Form F-1 filed with the SEC on March 28, 2018.	stock	

CUSIP No. H0381L104 Page 7 of 10

1.	Name o	f Reportin	ng Persons		
	Moniqu	ıe Saulniei	r ("Saulnier")		
2.			priate Box if a Member of a Group (see instructions)		
				(a) (b)	
3.	SEC US	SE ONLY			
4.	Source	of Funds (	(see instructions)		
	00				
5.	Check i	f Disclosu	re of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizens	ship or Pla	ice of Organization		
	Б. 1.	G: ··			
	French	Citizen 7.	Sole Voting Power		
		/.	Sole voting rower		
			0		
	Number of	8.	Shared Voting Power		
	Shares		331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC	VII may bo	Δ
	Beneficially		deemed to have sole voting power, and Saulnier, a managing partner of SP SAS, may be deemed to have		
	Owned by		to vote these shares.		
	Each Reporting	9.	Sole Dispositive Power		
	Person With		0		
		10.	Shared Dispositive Power		
			221 147 chaves all of which are or mod directly by of CC VII CD CAC the management company of CC	VIII march	
			331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC deemed to have sole voting power, and Saulnier, a managing partner of SP SAS, may be deemed to have		
			to vote these shares.		
11	. Aggrega	ate Amoui	nt Beneficially Owned by Each Reporting Person		
	331,147	shares			
12	. Check i	f the Aggı	regate Amount in Row (11) Excludes Certain Shares (see instructions)		
13	. Percent	of Class I	Represented by Amount in Row 11		
	5.4% (1	.)			
14			g Person (see instructions)		
	IN				
			s of Auris Medical Holding AG common stock issued and outstanding, which is the number of shares of common stock is a disclosed by Auris Medical Holding AG in its Form F-1 filed with the SEC on March 28, 2018.	non stock	

CUSIP No. H0381L104 Page 8 of 10

1.	Name o	f Reportii	ng Persons		
	Grazian	o Seghezz	zi ("Seghezzi")		
2.			priate Box if a Member of a Group (see instructions)		
				(a) (b)	
3.	SEC US	SE ONLY		(0)	
4.	Source	of Funds (	(see instructions)		
	00				
5.	Check i	f Disclosu	ure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizens	ship or Pla	ace of Organization		
	French (	Citizen			
		7.	Sole Voting Power		
			0		
		8.	Shared Voting Power		
	Number of Shares		221 147 chaves all of which are as mod directly by of CC VII CD CAC the management company of CC	VIII march	
	Beneficially		331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC deemed to have sole voting power, and Seghezzi, a managing partner of SP SAS, may be deemed to have		
	Owned by		to vote these shares.		
	Each Reporting	9.	Sole Dispositive Power		
	Person With		0		
		10.	Shared Dispositive Power		
			221 147 charge all of which are extract directly by of SC VII SD SAS, the management company of SC V	VII mar b	0
			331,147 shares, all of which are owned directly by of SC VII. SP SAS, the management company of SC V deemed to have sole voting power, and Seghezzi, a managing partner of SP SAS, may be deemed to have		
			to vote these shares.		
11.	Aggrega	ate Amou	nt Beneficially Owned by Each Reporting Person		
	331,147	' shares			
12.	Check i	f the Agg	regate Amount in Row (11) Excludes Certain Shares (see instructions) □		
13.	Percent	of Class 1	Represented by Amount in Row 11		
	5.4% (1	)			
14.	Type of	Reporting	g Person (see instructions)		
	IN				
			s of Auris Medical Holding AG common stock issued and outstanding, which is the number of shares of comn 018, as disclosed by Auris Medical Holding AG in its Form F-1 filed with the SEC on March 28, 2018.	ıon stock	
	-				

CUSIP No. H0381L104 Page 9 of 10

This Amendment No. 2 ("Amendment No. 2") amends and supplements the Schedule 13D (the "Schedule 13D") filed with the Securities and Exchange Commission (the "SEC") by Sofinnova Capital VII FCPR ("SC VII"), Sofinnova Partners SAS, a French corporation "SP SAS"), and Denis Lucquin ("Lucquin"), Antoine Papiernik ("Papiernik"), Monique Saulnier ("Saulnier"), the managing partners of SP SAS (collectively, the "Listed Persons" and together with SC VII and SP SAS, the "Filing Persons") on August 5, 2014. Rafaèle Tordjman ceased to be a managing partner of SP SAS on February 28, 2017, and is not a Listed Person on this Amendment No. 2. Graziano Seghezzi ("Seghezzi") and Henrijette Richter ("Richter") became managing partners of SP SAS and each is included as a Listed Person on this Amendment No. 2. Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported in the Schedule 13D, as amended. Capitalized terms used herein shall have the meanings ascribed to them in the Schedule 13D.

#### Item 5. Interest in Securities of the Issuer.

Item 5 is hereby amended by deleting it in its entirety and replacing it with the following:

- (a) See Rows 11 and 13 of the cover page for each of the Filing Persons. The Filing Persons disclaim beneficial ownership with respect to these shares except to the extent of their pecuniary interest therein.
- (b) See Rows 7, 8, 9, and 10 for each Filing Person.
- (c) SC VII sold shares of Common Stock of Auris Medical Holding AG (the "Common Stock") during the last 60 days in open market transactions on the following dates at the daily average prices indicated below:

<u>Date</u>	<u>Shares</u>	<u>Per Share</u> <u>Average Price</u>
February 26, 2018	220,910*	\$.2652
February 27, 2018	73,446*	<b>\$.2573</b>
February 28, 2018	669,867*	\$.2566
March 1, 2018	441,768*	\$.2568
March 2, 2018	594,009*	\$.2898
March 22, 2018	7,298	\$1.8000

<sup>\*</sup> Sale occurred prior to a 10-for-1 reverse stock split of the Common Stock effected on March 13, 2018.

- (d) Under certain circumstances set forth in the operating agreement of SC VII, the equity holders of SC VII and SAS, may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by SC VII.
- (e) Not applicable.

CUSIP No. H0381L104 Page 10 of 10

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 23, 2018

SOFINNOVA CAPITAL VII FCPR SOFINNOVA PARTNERS SAS

By: Sofinnova Partners SAS By: /s/ Monique Saulnier

Name: Monique Saulnier
Title: Managing Partner

Title: Managing Partner

By: /s/ Monique Saulnier
Name: Monique Saulnier

Name: Monique Saulnier
Title: Managing Partner

By: /s/ Denis Lucquin By: /s/ Monique Saulnier

Name: Denis Lucquin Name: Monique Saulnier

By: s/ Antoine Papiernik By: s/ Henrijette Richter

Name: Antoine Papiernik Name: Henrijette Richter

By: /s/ Graziano Seghezzi

Name: Graziano Seghezzi